XSPRAS Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr50.85 |
| 52 Week High | kr0 |
| 52 Week Low | kr0 |
| Beta | 0.81 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| XSPRAS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.0% |
| 1Y | n/a | -19.3% | 6.7% |
Return vs Industry: Insufficient data to determine how XSPRAS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how XSPRAS performed against the UK Market.
Price Volatility
| XSPRAS volatility | |
|---|---|
| XSPRAS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: XSPRAS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine XSPRAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 26 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include XS003 for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and XS004 for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
Xspray Pharma AB (publ) Fundamentals Summary
| XSPRAS fundamental statistics | |
|---|---|
| Market cap | kr1.15b |
| Earnings (TTM) | -kr180.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.4x
P/E RatioIs XSPRAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XSPRAS income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr180.39m |
| Earnings | -kr180.39m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 14, 2024
| Earnings per share (EPS) | -6.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XSPRAS perform over the long term?
See historical performance and comparison